Cyclooxygenase‐2 in oligodendroglial neoplasms

Although increased expression of cyclooxygenase‐2 (COX‐2) has been described in association with a variety of neoplasms, including tumors of astrocytic derivation, limited data are available on COX‐2 expression in oligodendrogliomas.

[1]  G. Butti,et al.  Arachidonic acid metabolic profiles in human meningiomas and gliomas , 2004, Journal of Neuro-Oncology.

[2]  G. Barnett,et al.  Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. , 2002, Annals of diagnostic pathology.

[3]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[4]  W. Hung,et al.  Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. , 2002, Human pathology.

[5]  H. Hollema,et al.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. , 2001, Cancer research.

[6]  E. Fosslien.  Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. , 2001, Annals of clinical and laboratory science.

[7]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[8]  K. Tabuchi,et al.  Expression of prostaglandin H synthase-2 in human brain tumors , 2001, Acta Neuropathologica.

[9]  M. Morohashi,et al.  Immunohistochemical expression of cyclooxygenase‐2 in skin cancers , 2001, Journal of cutaneous pathology.

[10]  R. Langenbach,et al.  Why there are two cyclooxygenase isozymes. , 2001, The Journal of clinical investigation.

[11]  T. Shono,et al.  Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.

[12]  W. Ichikawa,et al.  Depth of invasion parallels increased cyclooxygenase‐2 levels in patients with gastric carcinoma , 2001, Cancer.

[13]  J. Masferrer,et al.  COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.

[14]  H. Schluesener,et al.  Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression , 2000, Brain Research.

[15]  P. Unger,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. , 2000, Urology.

[16]  P. Abel,et al.  Cytoplasmic induction and over‐expression of cyclooxygenase‐2 in human prostate cancer: implications for prevention and treatment , 2000, BJU international.

[17]  P. Black,et al.  Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. , 2000, Cancer research.

[18]  R. Prayson,et al.  Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. , 2000, Annals of diagnostic pathology.

[19]  F. Lang,et al.  Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Weller,et al.  Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo , 1999, Acta Neuropathologica.

[22]  M. Westphal,et al.  Thromboxane synthase regulates the migratory phenotype of human glioma cells. , 1999, Neuro-oncology.

[23]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[24]  Anderson,et al.  Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study , 1998, Neuropathology and applied neurobiology.

[25]  H. Korf,et al.  Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases , 1998, Acta Neuropathologica.

[26]  S. Wharton,et al.  Proliferation and cell death in oligodendrogliomas. , 1998, Neuropathology and applied neurobiology.

[27]  S. Coons,et al.  The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. , 1997, Neurosurgery.

[28]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[29]  J. Otto,et al.  Photolabeling of Prostaglandin Endoperoxide H Synthase-1 with 3-Trifluoro-3-(m-Iiodophenyl)diazirine as a Probe of Membrane Association and the Cyclooxygenase Active Site (*) , 1996, The Journal of Biological Chemistry.

[30]  S. Heegaard,et al.  Proliferating cell nuclear antigen and Ki‐67 immunohistochemistry of oligodendrogliomas with special reference to prognosis , 1995, Cancer.

[31]  J. Goldblum,et al.  Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  H. Blomgren,et al.  Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. , 1992, Anticancer research.

[33]  T. Seed,et al.  Ultrastructural evidence for differentiation in a human glioblastoma cell line treated with inhibitors of eicosanoid metabolism. , 1990, Neurosurgery.

[34]  M. Bergström,et al.  Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids. , 1990, European journal of cancer.

[35]  R. McLendon,et al.  Clinicopathologic correlations in the oligodendroglioma , 1987, Cancer.

[36]  J. Bruner.  Oligodendroglioma. Histologic evaluation and prognosis. , 1986, Journal of neuropathology and experimental neurology.

[37]  R. Tubbs,et al.  Immunohistology of lymphoproliferative disorders. , 1984, Seminars in diagnostic pathology.